CMS Proposes To Cover J&J's Natrecor For Labeled Indication Only
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS' proposed national coverage determination would not provide Medicare coverage of nesiritide for chronic heart failure.
You may also be interested in...
J&J’s Natrecor Out Of Medicare For Chronic Heart Failure
CMS’ final national coverage determination does not change contractor discretion to cover other off-label uses.
J&J’s Natrecor Out Of Medicare For Chronic Heart Failure
CMS’ final national coverage determination does not change contractor discretion to cover other off-label uses.
Natrecor Sales & Marketing Subject Of Federal Prosecutor's Subpoena
U.S. Attorney's Office in Boston is seeking "documents related to the sales and marketing" of the congestive heart failure therapy, J&J division Scios says. Subpoena announcement comes on the heels of a journal article asserting that Scios engaged in a marketing campaign for outpatient use of the drug, which the company denies.